5-iodo-benzo[b]thiophene-2-carboxylic acid ethyl ester | 13771-70-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 5-iodo-benzo[b]thiophene-2-carboxylic acid ethyl ester
• 英文别名: 5-iodo-benzo[b]thiophene-2-carboxylic acid ethyl ester；5-iodobenzo[b]thiophene-2-carboxylic acid ethyl ester；ethyl 5-iodobenzo[b]thiophene-2-carboxylate；2-ethoxycarbonyl-5-iodobenzothiophene；2-Carbethoxy-5-iod-benzothiophen；ethyl 5-iodo-1-benzothiophene-2-carboxylate
• CAS: 13771-70-5
• 化学式: C₁₁H₉IO₂S
• 分子量: 332.162
• InChiKey: BZSXRTIPOXRLPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-iodo-benzo[b]thiophene-2-carboxylic acid ethyl ester 在 异丙基溴化镁 、 三乙酰氧基硼氢化钠 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 生成 ethyl 5-((phenylamino)methyl)benzo[b]thiophene-2-carboxylate
  参考文献：
  名称：

  Benzo[b]thiophene-based histone deacetylase inhibitors

  摘要：

  Benzo[b]thienyl hydroxamic acids, a novel class of historic deacetylase (HDAC) inhibitors, were identified via a targeted screen of small molecule hydroxamic acids. Various substitutions were explored in the C5- and C6-positions of the benzo[b]thiophene core to characterize SAR and develop optimal inhibitors. It was determined that substitution at the C6-position of the benzo[b]thiophene core with a three-atom spacer yielded optimal HDAC I inhibition and anti-proliferative activity in murine erythroleukemia (SC-9) cells. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.091
• 作为产物：
  描述：

  5-氨基-1-苯并噻吩-2-羧酸乙酯 在 盐酸 、 sodium nitrite 、 sodium iodide 作用下， 以 水 为溶剂， 反应 2.17h， 生成 5-iodo-benzo[b]thiophene-2-carboxylic acid ethyl ester
  参考文献：
  名称：

  WO2006/115845

  摘要：

  公开号：

文献信息

• Peptide derivatives useful in treating autoimmune diseases
  申请人：Zeneca Limited

  公开号：US06087336A1

  公开（公告）日：2000-07-11

  The invention concerns pharmaceutically useful peptide derivatives of the formula (I): P--R.sup.1 --R.sup.2 --R.sup.3 --R.sup.4, in which P, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 have the various meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell mediated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

  该发明涉及具有以下式（I）的药用肽衍生物：P--R.sup.1 --R.sup.2 --R.sup.3 --R.sup.4，其中P，R.sup.1，R.sup.2，R.sup.3和R.sup.4具有本文中定义的各种含义，以及它们的药用盐和含有它们的药物组合物。这些新型肽衍生物在治疗MHC-II依赖的T细胞介导的自身免疫或炎症性疾病方面具有价值，例如类风湿性关节炎。该发明还涉及新型肽衍生物的制造过程以及化合物在医疗治疗中的使用。
• Thiophene and Benzothiophene Hydroxamic Acid Derivatives
  申请人：Miller A. Thomas

  公开号：US20070213392A1

  公开（公告）日：2007-09-13

  The present invention relates to a novel class of hydroxamic acid derivatives having a benzothiophene or thiophene backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit historic deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

  本发明涉及一种新型的羟胺酸衍生物，其具有苯并噻吩或噻吩骨架。这些羟胺酸化合物可用于治疗癌症。这些羟胺酸化合物还可以抑制组蛋白去乙酰化酶，并适用于选择性诱导末端分化，阻止肿瘤细胞的生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物对于治疗具有肿瘤细胞增殖特征的患者是有用的。本发明的化合物还适用于预防和治疗TRX介导的疾病，例如自身免疫性、过敏性和炎症性疾病，以及预防和/或治疗中枢神经系统（CNS）疾病，例如神经退行性疾病。本发明还提供了包含羟胺酸衍生物的药物组合物和这些药物组合物的安全剂量方案，其易于遵循，并且在体内产生治疗有效量的羟胺酸衍生物。
• Benzothiophene hydroxamic acid derivatives
  申请人：Hubbs Jed Lee

  公开号：US20090069391A1

  公开（公告）日：2009-03-12

  The present invention relates to a novel class of hydroxamic acid derivatives. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

  本发明涉及一种新型的羟基酰胺衍生物。这些羟基酰胺化合物可用于治疗癌症。这些羟基酰胺化合物还可以抑制组蛋白去乙酰化酶，并适用于选择性诱导末端分化、阻止肿瘤细胞生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物可用于治疗具有肿瘤细胞增殖特征的患者。本发明的化合物还可用于预防和治疗TRX介导的疾病，如自身免疫、过敏和炎症性疾病，以及预防和/或治疗中枢神经系统（CNS）疾病，如神经退行性疾病。本发明还提供包含羟基酰胺衍生物的药物组合物以及这些药物组合物的安全剂量方案，这些方案易于遵循，并在体内产生治疗有效量的羟基酰胺衍生物。
• Benzothiophene derivatives
  申请人：Hubbs Jed Lee

  公开号：US20090082308A1

  公开（公告）日：2009-03-26

  The present invention relates to a novel class of benzothiophene amide derivatives. The hydroxamic acid compounds can be used to treat cancer. The benzothiophene amide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

  本发明涉及一类新型的苯并噻吩酰胺衍生物。这些羟肟酸化合物可用于治疗癌症。苯并噻吩酰胺化合物还可以抑制组蛋白去乙酰化酶，并适用于选择性诱导终末分化，阻止肿瘤细胞的生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物可用于治疗具有肿瘤细胞增殖特征的患者。该发明的化合物也可用于预防和治疗TRX介导的疾病，如自身免疫性、过敏性和炎症性疾病，以及中枢神经系统（CNS）疾病的预防和/或治疗，如神经退行性疾病。本发明还提供了包含羟肟酸衍生物的药物组合物和这些药物组合物的安全剂量方案，易于遵循，并在体内产生治疗有效量的羟肟酸衍生物。
• Thiophene and benzothiophene hydroxamic acid derivatives
  申请人：Merck HDAC Research, LLC

  公开号：US07935724B2

  公开（公告）日：2011-05-03

  The present invention relates to a novel class of hydroxamic acid derivatives having a benzothiophene or thiophene backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit historic deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases, The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

  本发明涉及一种具有苯并噻吩或噻吩骨架的新型羟胺酸衍生物类。这些羟胺酸化合物可用于治疗癌症。羟胺酸化合物还可以抑制组蛋白去乙酰化酶，适用于选择性诱导终末分化，并阻止肿瘤细胞的生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物在治疗具有肿瘤细胞增殖特征的患者方面非常有用。本发明的化合物还可用于预防和治疗TRX介导的疾病，例如自身免疫、过敏和炎症性疾病，以及中枢神经系统（CNS）疾病的预防和/或治疗，例如神经退行性疾病。本发明还提供了包含羟胺酸衍生物的药物组合物和这些药物组合物的安全用量方案，这些方案易于遵循，并且在体内产生治疗有效量的羟胺酸衍生物。